SEATTLE, USA – News Direct – January 4, 2024 –
CAG Organic Products, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), today announced plans to construct a new manufacturing facility at AGC Inc.’s Technical Center in Yokohama, Japan. The new facility is part of CDMO’s strategic growth strategy to create more high-quality pharmaceutical development and manufacturing services in the Asia region that can help meet the global demand for biologics and therapy drugs advanced (ATMP). The facility is expected to be operational in 2026.
The new AGC Biologics facility in Yokohama will offer preclinical to commercial services for mammalian-based protein biologics, cellular therapies and messenger RNA (mRNA). The site will house several 2,000 L single-use bioreactors and several 4,000 L or larger reactors for mammalian cell culture services, making it one of the largest* sites in Japan in terms of capacity. mammal-based manufacturing, once completed.
(*AGC estimates)
AGC Biologics is building this facility with a grant from Japan’s Ministry of Economy, Trade and Industry (METI) as part of the ministry’s initiative to develop biopharmaceutical manufacturing sites to boost vaccine production In the region (announced in October 2022). The total investment for the AGC Biologics Yokohama site is expected to be approximately 50 billion Japanese yen (US$350,500,000) and once fully operational it will employ 400 people.
“Facing increased demand in this region for high-quality partners with a history of clinical and commercial biopharmaceutical manufacturing, we are making this investment to offer developers the services they need and strengthen our global CDMO network,” said Patricio Massera, Director Executive Director, AGC Biologics. “The new Yokohama facility will provide a central location for innovators in Japan and across the Asia-Pacific region, providing scientific expertise, technical flexibility and the services needed to support development and manufacturing at every critical stage. »
The Yokohama facility is expected to significantly contribute to the needs of regional and global developers seeking biopharmaceutical development and manufacturing capabilities, in addition to further maximizing operational and supply chain efficiencies across the global network from AGC Biologics. The company currently operates a site in the region, its
Chiba Facilityoffering mammalian expression and microbial fermentation services.
AGC Biologics is part of the Life Science business of AGC Inc. Life Science operates ten different facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients and agrochemicals.
To learn more about AGC Biologics’ global service network for protein biologics and cell and gene therapies, please visit
www.agcbio.com.
Hashtag: #AGCBiologics
The issuer is solely responsible for the content of this announcement.
